About ModernPeptideScience

Why this site exists

Peptide research is moving faster than most readers' ability to follow it. If you search for any specific peptide online, you'll typically find two kinds of content: dense scientific literature that's hard to parse without a biochem background, and marketing-inflected biohacker writeups that often overstate the evidence. The careful middle, peer-reviewed research curated and translated for an engaged non-specialist reader, is thin.

ModernPeptideScience fills that middle. Every peptide page summarizes the research at three tiers: human research (the highest standard), preclinical and emerging research (how mechanism is typically established), and reported user experiences (framed as hypothesis-generating signals rather than evidence). The goal is calibration, helping readers understand what's well-established, what's promising, and what's still being built.

What you'll find on this site

The site is organized into seven major sections, each serving a distinct purpose:

• Peptides, 96 individual peptide pages with mechanism, human and preclinical evidence, claims with verdicts, FAQs, and PubMed-cited references.
• GLP-1 Hub, The deepest hub on the site, covering approved obesity and diabetes drugs, emerging incretin candidates, head-to-head comparisons, and the trials reshaping the field.
• Articles, 93 practical long-form articles: comparisons, side-effect timelines, prevention strategies, and answers to the questions people actually ask about GLP-1s and peptides.
• Stacks, 40 theoretical peptide combinations as discussed in research and biohacker communities, with explicit evidence-grading and clear framing throughout.
• Evidence vs Myth, 26 practical reads on contested claims, popular discussion topics, and frequently misrepresented findings.
• Applications, Discovery directory organizing peptides by goal (weight loss, recovery, longevity, cognition, sleep, gut health, vascular health, and more).
• Emerging Peptides, 34 Phase 3 candidates, mid-stage compounds, and preclinical biology at the frontier of peptide research.

How we work

• Every factual statement is intended to tie to a cited source. Every peptide page includes its reference list, with PubMed links for primary research.
• Three evidence tiers (Established / Promising / Emerging) are applied consistently across compounds, so readers can compare across the catalog.
• We are explicit about what we don't yet know. Where controlled human trials haven't been conducted, we say so.
• We treat single-research-group literature carefully (BPC-157, the Khavinson short peptides), label anecdotal reports unambiguously, and revise pages when major new data publishes.
• We update content when new trial readouts publish, regulatory decisions change the landscape, or our reading of the evidence shifts.

The editorial process

Each peptide page and article goes through a consistent process:

1. Research: We read the primary literature (PubMed-indexed peer-reviewed publications first; conference proceedings, preprints, and regulatory filings second; well-curated review articles third).
2. Drafting: Content is structured around the same template, mechanism, human evidence, preclinical evidence, claims with verdicts, FAQs, references, so readers can navigate consistently across compounds.
3. Calibration: Every substantive claim is assigned to a verdict tier (Supported / Plausible / Preliminary / Uncertain / Unsupported / Established) so readers can quickly gauge what kind of evidence sits behind each statement.
4. Cross-checking: Claims that seem too good or too dismissive trigger a second look at the underlying source material. We are particularly cautious with lineage-concentrated literature (single research group dominance), preprint findings, and grey-market vendor claims.
5. Review and revision: Pages are revised when new data publishes, when we identify gaps or errors, or when reader feedback raises legitimate corrections.

What we don't do

• We do not sell peptides. The site is educational, not commercial in that sense.
• We do not provide dosing protocols, titration schedules, or instructions for personal use.
• We do not offer medical advice. Nothing here replaces a qualified clinician.
• We do not pretend the peer-reviewed literature is the final word, new data arrives constantly, and our reads update when it does.
• We do not endorse specific vendors, manufacturers, or commercial products beyond noting their regulatory status and the available research on them.

Who writes this

ModernPeptideScience is written and edited by Ronan Cross, the site's founding editor. Ronan spent two decades in the fitness world, competing at different points as both a bodybuilder and a powerlifter, and studied pre-med with an eye toward endocrinology before his path turned toward building and running his own business. He holds no clinical credentials — this site is not written by a doctor — but the interest in endocrinology never faded. Over nearly thirty years it grew into a steady focus on metabolic and longevity science, and a lasting habit of reading the primary literature for himself.

Two decades of watching the fitness industry sell overstated, and often outright false, claims left him with a reflexively critical eye. He treats almost no claim as credible until he has traced it back to the underlying research, and that skepticism is the editorial standard of this site: research first, community and anecdote clearly labeled as such, and no confident conclusions the evidence cannot support. GLP-1 drugs are his sharpest example of why it matters — a class he had long assumed was pharmacologically impossible, until the evidence forced him to reconsider what these molecules can actually do.

Ronan Cross is a pen name, used as a single consistent byline so the editorial voice stays accountable across the site while the focus stays on the evidence rather than the author.

Where individual authors contribute (subject-matter experts, clinicians offering specific perspectives, guest analysts on particular trials), we plan to identify them explicitly with the relevant credentials and disclosures. The aspiration is a transparent contributor model where readers can see who wrote what and assess it on the substance.

Editorial independence and disclosures

Editorial decisions, what to cover, how to evaluate the evidence, how to frame claims, are made independently of any commercial considerations. This is the point of the site, and we hold that line. As ModernPeptideScience grows, we will be transparent about the operating model that supports the work, and any commercial relationships will be disclosed clearly so readers can evaluate the editorial alongside that context.

The site does not currently accept advertising from peptide vendors or manufacturers. It does not participate in affiliate-link arrangements with research peptide retailers. The newsletter does not promote commercial products as editorial content. If these positions ever change, we will disclose the change visibly at the affected content.

Corrections

We care more about being right than being first. If you believe a claim on this site overstates, understates, or misrepresents the data, we want to hear about it. Corrections are tracked, credited, and reflected in updated content. Substantive corrections that change a verdict, claim, or recommendation are noted in the article's update history. Minor corrections (typos, broken links, formatting) are made silently.

To report a correction or factual concern, email info@modernpeptidescience.com with the URL, the specific claim in question, and (if possible) the source you believe should be cited instead.

See also

• Editorial methodology, how we evaluate, tier, and present evidence
• Disclaimers, medical, legal, and safety framing
• Browse all peptides, the complete index
• Articles, practical long-form guides
• Evidence vs Myth, practical reads on contested claims
• Research Library, aggregate citation index